Малта - Енглески - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - rasagiline - tablet - rasagiline 1 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - rasagiline - tablet - rasagiline 1 mg - anti-parkinson drugs

Малта - Енглески - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - rasagiline - tablet - rasagiline 1 mg - anti-parkinson drugs

Европска Унија - Енглески - EMA (European Medicines Agency)

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline mesylate 1 mg - azilect (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. the effectiveness of azilect was demonstrated in patients with early parkinson's disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy. the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinson's disease who were treated with levodopa. enter section text here azilect is contraindicated for use with meperidine. serious adverse reactions have been precipitated with concomitant use of meperidine (e.g., demerol and other tradenames) and mao inhibitors (maois) including selective mao-b inhibitors. these adverse reactions are often described as "serotonin syndrome", a potentially serious condition, which can result in death. typical clinical signs and symptoms include behavioral and cognitive/mental status changes (e.g., confusion, hypomania

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

teva neuroscience, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - azilect (rasagiline tablets) is indicated for the treatment of parkinson’s disease (pd). azilect is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of azilect and initiation of treatment with these medications. azilect is contraindicated for use with st. john’s wort and with cyclobenzaprine. azilect is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of azilect in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in combination

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 1 mg - azilect (rasagiline tablets) is indicated for the treatment of parkinson’s disease (pd). azilect is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of azilect and initiation of treatment with these medications. azilect is contraindicated for use with st. john’s wort and with cyclobenzaprine. azilect is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. pregnancy category c there are no adequate and well-controlled studies of rasagiline in pregnant women. azilect should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in a combined mating/fertility and embryo-fetal development study in pregnant rats, no effect on embryo-fetal development was observed at oral doses up to 3 mg/kg/da

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

flynn pharma ltd - rasagiline - tablet - 1mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: purified talc; citric acid monohydrate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; maize starch; stearic acid - pharmacor rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; stearic acid; purified talc; citric acid monohydrate; maize starch - akm rasagiline is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.